Cost Considerations for the Application of Continuous Processing
02nd October 2019 | 3:00 PM India Standard Time/ 10:30 AM GMT | Narasimha Rao Nedunuri, CEO of CLONZ Biotech and José Castillo, PhD, CTo and co-founder of Univercells |BOOK FREE SEAT
- Cost contribution of continuous manufacturing both in operational and capital expenditure in Monoclonal antibody production.
- Evaluating cost of production per gram conventional fed batch vs continuous process.
- Key considerations for adapting continuous process for the production of Biosimilar MAbs.
Presented by Narasimha Rao Nedunuri, CEO of CLONZ Biotech
And José Castillo, PhD, CTo and co-founder of Univercells
After working as the head of viral vaccine industrialization at GSK Vaccines, he started up Artelis with a small group of developers in 2006. At Artelis, he designed and developed bioreactors that transformed industrial operations. With his team, he developed the iCellis system and transferred it for more than 50 viral processes over the world. The technology is now marketed by PALL, where Jose held the position of Director of Cell Culture Technologies. With the same group of developers, he started up Univercells in 2013, aiming to develop disruptive manufacturing platforms that significantly impact affordability to vaccines and antibodies.
With a background in Chemical Engineering, Jose’s education includes a PhD in Applied Sciences from the Université libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School. As Univercells’ CTO, he is now the architect of highly efficient production processes that will make cell culture available and affordable for all. The goal is to disrupt the industry and become the leader of comprehensive manufacturing solutions.
Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines – for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost.
The company’s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches.
Deployment of affordable production units enables ‘in-country, for-country’ biologics production, creating value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients’ access to healthcare.
Univercells was founded in 2013 by experienced entrepreneurs Hugues Bultot, CEO, and José Castillo, CTO, who bring close to 25 years of expertise in the biotechnology and life sciences sectors. Headquartered in Gosselies (Belgium), Univercells benefits from support from the Walloon region, and received €3 million from Takeda in 2015. Most recently, the company was awarded a $12 million grant from the Bill & Melinda Gates Foundation.